PMID- 36351648
OWN - NLM
STAT- MEDLINE
DCOM- 20221111
LR  - 20221111
IS  - 0485-1439 (Print)
IS  - 0485-1439 (Linking)
VI  - 63
IP  - 10
DP  - 2022
TI  - [Busulfan/thiotepa followed by autologous peripheral blood stem cell 
      transplantation for refractory diffuse large B-cell lymphoma accompanied by 
      hypopyon].
PG  - 1409-1414
LID - 10.11406/rinketsu.63.1409 [doi]
AB  - A 54-year-old male patient, who presented with multiple lymphadenopathies, 
      bilateral leg edema, and oscheohydrocele, was diagnosed with diffuse large B-cell 
      lymphoma (DLBCL) stage IVB. His lymphadenopathies disappeared after six courses 
      of R-CHOP therapy, which consist of rituximab, cyclophosphamide, doxorubicin, 
      vincristine, and prednisolone); however, right hypopyon and partly remaining 
      testicular soft tissue masses with fluorodeoxyglucose accumulation were observed. 
      Lymphoma cell infiltration was observed in the aqueous humor of the right 
      anterior chamber and testis, which indicates DLBCL progression. Hypopyon 
      disappeared after the first course of intrathecal chemotherapy combined with 
      R-HDMA therapy, which consists of rituximab and high-dose 
      methotrexate/cytarabine, but recurred in the third course. The patient then 
      underwent busulfan and thiotepa (BuTT) therapy followed by autologous peripheral 
      blood stem cell transplantation (auto-PBSCT) after four courses of R-HDMA 
      therapy. Hypopyon promptly disappeared after BuTT therapy and no hypopyon 
      recurrence was observed 9 months after auto-PBSCT. Therefore, BuTT therapy is 
      effective for hypopyon associated with refractory DLBCL.
FAU - Kodama, Yosuke
AU  - Kodama Y
AD  - Department of Hematology, Oita Prefectural Hospital.
FAU - Saburi, Masuho
AU  - Saburi M
AD  - Department of Hematology, Oita Prefectural Hospital.
FAU - Maruyama, Rika
AU  - Maruyama R
AD  - Department of Hematology, Oita Prefectural Hospital.
FAU - Sakata, Masanori
AU  - Sakata M
AD  - Department of Hematology, Oita Prefectural Hospital.
FAU - Takata, Hiroyuki
AU  - Takata H
AD  - Department of Hematology, Oita Prefectural Hospital.
FAU - Miyazaki, Yasuhiko
AU  - Miyazaki Y
AD  - Department of Hematology, Oita Prefectural Hospital.
FAU - Kawano, Katsuya
AU  - Kawano K
AD  - Department of Clinical Laboratory Technology, Oita Prefectural Hospital.
FAU - Wada, Junpei
AU  - Wada J
AD  - Department of Pathology, Oita Prefectural Hospital.
FAU - Urabe, Shogo
AU  - Urabe S
AD  - Department of Pathology, Oita Prefectural Hospital.
FAU - Hazuku, Tomonobu
AU  - Hazuku T
AD  - Department of Ophthalmology, Oita Prefectural Hospital.
FAU - Ohtsuka, Eiichi
AU  - Ohtsuka E
AD  - Department of Hematology, Oita Prefectural Hospital.
LA  - jpn
PT  - Case Reports
PT  - English Abstract
PT  - Journal Article
PL  - Japan
TA  - Rinsho Ketsueki
JT  - [Rinsho ketsueki] The Japanese journal of clinical hematology
JID - 2984782R
RN  - 905Z5W3GKH (Thiotepa)
RN  - G1LN9045DK (Busulfan)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - 129273-26-3 (N-hydroxysuccinimidyl 
      digoxigenin-3-O-methylcarbonyl-epsilon-aminocaproate)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Male
MH  - Humans
MH  - Middle Aged
MH  - Thiotepa/therapeutic use
MH  - Busulfan
MH  - *Peripheral Blood Stem Cell Transplantation
MH  - Rituximab
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - *Lymphoma, Large B-Cell, Diffuse/therapy/drug therapy
MH  - Transplantation, Autologous
MH  - *Lymphoma, Non-Hodgkin/drug therapy
MH  - Cyclophosphamide/therapeutic use
MH  - Vincristine/therapeutic use
MH  - Doxorubicin/therapeutic use
MH  - *Lymphadenopathy/drug therapy
OTO - NOTNLM
OT  - Autologous peripheral blood stem cell transplantation
OT  - Diffuse large B-cell lymphoma
OT  - Hypopyon
OT  - Thiotepa
EDAT- 2022/11/10 06:00
MHDA- 2022/11/15 06:00
CRDT- 2022/11/09 20:04
PHST- 2022/11/09 20:04 [entrez]
PHST- 2022/11/10 06:00 [pubmed]
PHST- 2022/11/15 06:00 [medline]
AID - 10.11406/rinketsu.63.1409 [doi]
PST - ppublish
SO  - Rinsho Ketsueki. 2022;63(10):1409-1414. doi: 10.11406/rinketsu.63.1409.